+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the use of personalized, dynamic titanium prostheses made with 3D printing to reconstruct the chest wall after tumor removal or severe trauma. This study addresses the challenges of traditional rigid reconstruction methods that can cause pain or breathing difficulties by testing implants designed to mimic natural rib movement, potentially improving function and comfort. The study is a multicenter, ambispective registry collecting both retrospective and prospective data across major Spanish hospitals. The treatment involves creating a custom 3D-printed titanium prosthesis based on preoperative CT scans, manufactured using titanium alloy powder. During surgery, the prosthesis is implanted and anchored to the ribs or sternum to restore chest wall integrity while preserving natural dynamics. The study includes retrospective cases and prospective enrollment over 24 months, with follow-up evaluations at discharge, 1 month, 6 months, and 12 months post-surgery. Participants will undergo assessments including pulmonary function tests, pain scales, imaging like X-rays and CT scans, and quality of life questionnaires. Data is securely stored and anonymized in a centralized database compliant with European data protection laws. The primary outcomes measure changes in lung function parameters over one year. Participants can withdraw at any time, and the study aims to improve prosthesis design and surgical practices through comprehensive monitoring and analysis.

Age: 18Years +All GendersPhase Not Applicable
5 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
R

Actively Recruiting

Researchers are evaluating the effects of teplizumab compared with a placebo in individuals aged 1 to 25 years who have recently been diagnosed with Stage 3 type 1 diabetes. This Phase 3, multicenter, randomized, double-blind study aims to measure changes in blood sugar control and the ability to reduce prandial insulin use over 52 weeks. Both groups will continue their standard insulin therapy during the study. Participants will receive either teplizumab or a matching placebo through intravenous infusions, with teplizumab doses gradually increasing. The study includes two groups one receiving the study drug and the other receiving placebo infusions. The total study period for each participant lasts about 84 weeks 19 months, during which participants are closely monitored. Throughout the study, participants will be regularly evaluated for blood sugar levels, insulin use, and markers of diabetes control including glycated hemoglobin HbA1c, C-peptide levels, and glucose monitoring. Safety will be assessed by tracking adverse events and immune responses. The research team will monitor participants at specified intervals up to 78 weeks to assess treatment effects and safety.

Age: 1Year - 25YearsAll GendersPhase 3
202 locations
P

Actively Recruiting

Researchers are studying adults aged 18 and older with warm autoimmune hemolytic anemia wAIHA, a condition where the immune system destroys red blood cells. This Phase 3 trial evaluates the effects, safety, and how the body processes rilzabrutinib compared with a placebo. The goal is to see if rilzabrutinib can increase hemoglobin levels sustainably in participants who have had the disease for at least six months and have not responded well to corticosteroid treatments. Participants will be randomly assigned in a 21 ratio to receive either oral rilzabrutinib or a placebo twice daily during the primary analysis period lasting up to 24 weeks. Those who complete this period can enter an open-label phase lasting 28 weeks where all receive rilzabrutinib. Participants who show improved hemoglobin levels near the end of this phase may continue in a long-term extension that lasts up to 52 weeks from the start of the extension. The study includes a safety follow-up of two weeks after treatment completion or discontinuation. Throughout the study, participants will have multiple visits for assessments including blood tests to measure hemoglobin changes, fatigue levels, and lung function, among others. Researchers will monitor for side effects, vital signs, and laboratory values up to 104 weeks. The primary outcome is the proportion of participants achieving a durable hemoglobin response between weeks 12 and 24. Secondary outcomes include overall hemoglobin response, fatigue improvement, and safety events. The total study duration for participants may extend up to several years depending on eligibility for the long-term extension.

Age: 18Years +All GendersPhase 3
105 locations
P

Actively Recruiting

Gastrointestinal Stromal Tumor GIST is a type of soft tissue tumor that forms in the digestive system, often in the stomach or small intestine, caused by changes in certain proteins leading to uncontrolled cell growth. This research is evaluating the drug velzatinib GSK6042981 in adults with newly diagnosed metastatic or unresectable GIST, comparing it to the standard treatment imatinib to see if it can delay disease progression and assess safety and tolerability. Participants will be randomly assigned to receive either velzatinib or imatinib, with treatments given according to study protocols. The study will monitor each participant over time to compare the effects of these medications on tumor growth and patient health. Throughout the trial, participants will undergo regular assessments including imaging scans reviewed by independent central review, evaluations of tumor response, survival tracking, safety monitoring of side effects and vital signs, and quality of life questionnaires. The study will last for up to approximately 74 to 75 months, with ongoing evaluations to measure progression-free survival and other important outcomes.

Age: 18Years +All GendersPhase 3
93 locations
S

Actively Recruiting

Researchers are evaluating the reactogenicity, safety, and immune response of two doses of PED-HZsu, GlaxoSmithKlines vaccine candidate, for preventing Herpes Zoster in immunocompromised children aged 1 to 17 years who have had a kidney transplant. This Phase 12 study focuses on pediatric renal transplant recipients to understand how the vaccine performs in this vulnerable group. Participants are divided by age and treatment into four groups children aged 12 to 17 receiving the vaccine, similar-aged children receiving standard care without the vaccine, children aged 1 to 11 receiving the vaccine, and the youngest group receiving standard care. Vaccinated groups receive two intramuscular doses of PED-HZsu in the deltoid muscle on day 1 and one month later. The younger age group enrollment is staggered, starting after safety data from the older group is reviewed. During the study, participants are monitored closely for local and general adverse events within seven days after each vaccination, as well as unsolicited adverse events and serious safety concerns up to two months post-vaccination. Researchers measure antibody levels one month after the second dose to assess immune response. Follow-up continues up to 13 months to track serious events, kidney transplant rejection, and occurrence of Herpes Zoster. The study includes careful assessment of seizures and other potential side effects related to the vaccine.

Age: 1Year - 17YearsAll GendersPhase 1Phase 2
31 locations
F

Actively Recruiting

Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.

All AgesAll Genders
284 locations
P

Actively Recruiting

Researchers are evaluating the efficacy of perioperative dostarlimab compared with the standard of care in participants with untreated T4N0 or Stage III resectable colon cancer that shows defective mismatch repair or high microsatellite instability dMMRMSI-H. This phase 3, open-label, randomized study focuses on these specific colon cancer patients to assess if dostarlimab can improve outcomes compared to current treatments. Participants are randomly assigned to receive either dostarlimab before and after surgery or the standard of care treatments, which include FOLFOX or CAPEOX chemotherapy or post-surgery observation. Dostarlimab is given as monotherapy during the perioperative period. The study carefully monitors participants for up to approximately 5 years to evaluate long-term effects. During the trial, participants undergo regular assessments including event-free survival reviewed by blinded independent central review, overall survival, and pathological response evaluations. Safety is closely monitored by tracking adverse events, immune-related effects, and serum concentrations of dostarlimab across treatment cycles. The study involves frequent follow-ups to understand treatment impact and ensure participant well-being throughout the extended observation period.

Age: 18Years +All GendersPhase 3
266 locations